Increased expression of plasma soluble ACE2 was found in patients with myocardial infarction, atrial fibrillation, valvular disease, and heart failure, reflecting a higher basal ACE2 expression and increased susceptibility in this population (García-Escobar et al., 2022; Silva et al., 2022). Here, ACE2 is linked to heart failure.